Tim FerrissWhat Most Has My Attention Right Now — Credible (vs. Bogus) Vagus Nerve Stimulation
CHAPTERS
- 0:00 – 0:38
Kelly Owens’ dramatic turnaround in a VNS clinical trial
The episode opens with Dr. Kevin J. Tracey recounting how Kelly Owens, long disabled by Crohn’s disease complications, experienced a striking improvement after receiving an implanted device in a European trial. He describes a pivotal moment in Amsterdam when she unexpectedly ran up train stairs, stunning her husband. The story sets the emotional and clinical stakes for the rest of the discussion.
- •Kelly Owens’ long history of severe inflammatory illness, disability, and mobility limitations
- •The Amsterdam stair-running moment as a visible sign of improvement after implantation
- •The later email thanking Dr. Tracey and how it impacted him
- •How patient stories can catalyze broader interest in bioelectronic medicine
- 0:38 – 5:42
Why Tim ignored VNS for years—and what changed his mind
Tim Ferriss explains his prior skepticism due to online misinformation, questionable devices, and his doubts about polyvagal theory. His perspective shifts after a highly technical friend reports large heart rate variability changes and shares citations. Tim then finds Dr. Tracey’s work through an interview and Dr. Tracey’s book, prompting this conversation.
- •Concerns about charlatans, low-credibility marketing, and risky products associated with “vagus” claims
- •Tim’s skepticism after encountering polyvagal theory
- •A technical investor friend’s personal experience and literature deep-dive prompting renewed attention
- •Tim’s path to Dr. Tracey via an interview and The Great Nerve book
- 5:42 – 8:01
SetPoint Medical’s FDA approval and the “inflammatory reflex” concept
Dr. Tracey shares the headline: SetPoint Medical received FDA approval for a vagus nerve stimulation device to treat rheumatoid arthritis. He frames the device as activating an evolutionarily conserved reflex that suppresses runaway inflammation. He also notes the work rests on decades of research replicated across many labs.
- •FDA approval for a vagus nerve stimulation device targeting rheumatoid arthritis
- •The vagus nerve as “brakes” on inflammation via what Dr. Tracey calls the inflammatory reflex
- •The research arc spanning roughly two decades and broad replication by other labs
- •Patient impacts described in terms of regained function in long-standing rheumatoid arthritis
- 8:01 – 15:47
Kelly Owens’ full backstory: severe systemic inflammation, risks, and backlash
Dr. Tracey expands on Kelly Owens’ trajectory from early symptoms to years of disability, extensive medical care, and life constraints. He explains how she entered the Amsterdam trial and the specific implant setup used. He also describes skepticism she faced, industry pushback, and the symbolic cane she gifted him.
- •Crohn’s disease complications affecting joints and systemic health; chronic fatigue and mental health impacts discussed
- •How Kelly relocated to participate in a European clinical trial and received an early-generation implant
- •Warnings about resistance to new modalities and accusations of placebo
- •A pharmaceutical executive’s hostile reaction and the cane gift as motivation for the research team
- 15:47 – 20:00
Tim’s broader “connective tissue” hypothesis: bioelectric medicine, inflammation, and mood
Tim lays out why VNS has become personally compelling, tying together experiences with brain stimulation, interest in alternatives to biologics, and questions about inflammation in depression and neuroinflammation. He references observations from microbiome research, diet strategies, and pharmaceutical examples that seem to depend on vagal pathways. This sets up a shift into core definitions.
- •Interest in bioelectric medicine examples Tim cites (e.g., TMS, focused ultrasound) as context for VNS curiosity
- •Motivation to find alternatives to medications with significant side effects
- •Tim’s focus on inflammation as a potential shared driver across multiple conditions, including mood stability
- •Examples Tim mentions where effects seem to depend on an intact vagus nerve, leading to “what’s going on?” questions
- 20:00 – 26:42
Vagus nerve anatomy and signaling: two nerves, hundreds of thousands of fibers, unknown code
Dr. Tracey explains the vagus nerve anatomically and functionally, emphasizing that there are two vagus nerves and about 100,000 fibers in each. He notes that most fibers carry information from body to brain, while a smaller portion runs brain to body. He highlights how much remains unknown about the information “code” carried by these signals.
- •Two vagus nerves traveling from the base of the brain down the neck into chest and abdomen
- •Each side contains ~100,000 fibers; most originate in the body and carry signals to the brain
- •Vagus fibers branch extensively and interface with cells or other nerves
- •Open research question: what the signals encode beyond measurable action potentials
- 26:42 – 29:27
Turning off cytokines: the accident that led to bioelectronic inflammation control
Dr. Tracey explains that stimulating the correct vagus fibers can sharply reduce cytokine production. He recounts an accidental discovery during stroke research: a drug placed in the brain reduced inflammation in the body, which did not make sense given dosing and the blood-brain barrier. The team later traced the effect to vagus nerve activation, inspiring device-based therapy development.
- •Correct vagus stimulation can “turn off” cytokine production
- •Unexpected body-wide anti-inflammatory effect from a small-dose brain intervention
- •Reason it was puzzling: insufficient drug amounts to explain peripheral effects and blood-brain barrier considerations
- •The insight that electrodes could activate the same pathways as a drug-triggered vagus response
- 29:27 – 38:13
Bioelectronic medicine vs. pharma: start with mechanism, not hype
Dr. Tracey defines bioelectronic medicine as an approach that begins with a condition and mechanism, then identifies nerves that control the molecular targets in the body. He contrasts this with the pharmaceutical model of selecting a molecular target and developing drugs against it. He also cautions against overextending VNS to diseases where mechanisms are unclear, using asthma as an example.
- •Pharma workflow described: pick disease → identify molecular target → build drug
- •Bioelectronic workflow described: pick disease → identify nerve control of target → build device therapy
- •Warning that VNS claims must be grounded in known mechanisms
- •Asthma example: mechanism uncertainty and the “Mice Don’t Wheeze” cautionary line
- 38:13 – 44:09
Defining inflammation—and why controlling it could reshape health and longevity
Dr. Tracey defines inflammation in classic terms (redness, swelling, heat, pain) and explains its benefits when properly resolved. He then contrasts this with lower-grade inflammatory signatures observed in conditions like neurodegeneration and metabolic dysfunction. He argues that many leading causes of death are caused or worsened by inflammation and raises the question of what would happen if inflammation could be better controlled.
- •Inflammation as a helpful response that becomes harmful when it fails to resolve
- •Cytokines and other molecules as drivers, with different “flavors” of inflammation across tissues
- •Discussion of low-grade inflammation in aging and chronic disease contexts
- •Dr. Tracey’s broader framing: major global killers share inflammatory involvement; evolution built “brakes” via brain-to-vagus signaling
- 44:09 – 59:16
Safety and tradeoffs: VNS vs. biologics and the immunosuppression concern
Tim asks whether reducing cytokines could impair beneficial inflammation needed for immune defense or adaptation. Dr. Tracey contrasts biologics that can eliminate a cytokine’s activity with vagus-driven inhibition that reduces excessive levels without shutting them off completely. He points to decades of implanted VNS experience in epilepsy and depression without the infection/cancer risks associated with black-box immunosuppression warnings.
- •Biologics described as fully neutralizing specific cytokines and carrying black-box immunosuppression risks
- •Implanted VNS has decades of use history in depression/epilepsy with known surgical risks but no black-box immunosuppression profile described
- •VNS effect characterized as partial suppression (e.g., reducing toxic-range cytokine output to a safer range)
- •Discussion that VNS can modulate multiple cytokines together rather than one-at-a-time targeting
- 59:16 – 1:04:50
From self-help to serious illness: what VNS is (and isn’t) outside implants
The conversation shifts to practical distinctions between approaches for severely ill patients versus generally well people pursuing self-experimentation. Dr. Tracey emphasizes that only implanted electrodes (and experimentally focused ultrasound) directly and specifically stimulate the vagus nerve, and warns against mislabeling other methods as true VNS. He acknowledges that lifestyle factors like sleep, exercise, and stress reduction may influence vagal-related physiology while staying cautious about claims.
- •Implants framed as particularly relevant for patients with severe, disabling inflammatory disease and compliance challenges
- •Clear distinction: direct vagus stimulation requires implanted electrodes; focused ultrasound can target nerves experimentally
- •Non-invasive electrical methods (neck/ear/face) described as nonspecific and should not be marketed as true VNS
- •Lifestyle approaches discussed as potentially supportive but not positioned as cures for serious disease
- 1:04:50 – 1:14:04
Auricular stimulation origins, ear vagus anatomy, and what brain studies show
Dr. Tracey explains the surprising origins of modern auricular therapy maps, tracing them to a French physician in 1957 rather than ancient sources. He then describes the auricular branch of the vagus nerve reaching ear cartilage as a unique skin-accessible vagal pathway carrying sensory input to the brainstem. He reviews the mixed and inconsistent research landscape but notes partial overlap in brain regions activated by ear stimulation and implanted VNS, including areas tied to arousal and learning.
- •Auricular therapy map history attributed to Dr. Paul Nogier’s observations and later uptake into Chinese textbooks
- •The cymba concha as a cartilage region innervated by a sensory vagus branch feeding into the nucleus tractus solitarius
- •Evolutionary explanation offered: vestigial linkage to fish gill cartilage innervation
- •Brain imaging and neurophysiology studies show varied findings, but some overlap with implanted VNS activation patterns (e.g., locus coeruleus and cholinergic regions)
- 1:14:04 – 1:21:47
DARPA’s role and the cognition/neuroplasticity thread in implanted VNS
Tim and Dr. Tracey discuss how DARPA funding enabled early exploration of VNS as a then-radical idea, emphasizing DARPA’s “What if it’s yes?” culture. Dr. Tracey also recounts research showing cognitive performance improvements when implanted VNS devices were turned on, even in epilepsy patients who did not benefit for seizure control. This expands the story beyond inflammation into learning and brain network modulation.
- •DARPA support described as critical to pursuing early VNS anti-inflammatory work
- •Geoff Ling’s “What if it’s yes?” approach highlighted as a cultural driver of high-risk research
- •Cognition finding described: improved scores on learning tests when implanted VNS was activated
- •Broader implication raised: vagus inputs can influence brain regions involved in learning, memory, and alertness
- 1:21:47 – 1:33:59
Ulf Andersson’s depression turnaround, HRV complexity, and famotidine as a ‘pharmacological’ VNS stimulator
Dr. Tracey introduces Ulf Andersson, a retired professor and cytokine researcher, and tells how Ulf developed episodic serious depression after major surgery. Inspired by lab findings that ear TENS could reduce cytokine production in many healthy volunteers, Ulf adopted left-ear cymba concha stimulation twice daily and reports major life improvement, later adding antibiotics for intestinal bacterial overgrowth. The discussion then turns to HRV measurement challenges and culminates in Dr. Tracey’s claim that famotidine showed evidence of being a pharmacological vagus nerve stimulator in their COVID-era studies, which Ulf combined with ear stimulation for striking HRV/respiratory synchronization effects.
- •Ulf Andersson’s background in inflammation research and his post-surgery depression episodes
- •Lab observations described: ear TENS at the cymba concha reduced cytokine production capacity in many volunteers
- •HRV measurement cautions: different wearables and methods compute different metrics; irregular beats can distort statistics
- •Famotidine described as studied during COVID at Northwell and characterized as a pharmacological vagus nerve stimulator; Ulf’s combined use reportedly improved his measured overlap between breathing-linked variability and HRV
- 1:33:59 – 1:43:27
Inflammation-driven depression, interoception, and a call for better stratified studies
Dr. Tracey argues that depression likely has multiple causes and criticizes overfocus on serotonin as the sole explanatory model. He emphasizes evidence that inflammation can cause depression in animals and people, and that inflammatory signals can reach the brain via vagus pathways as part of interoception. He calls for studies that group depressed patients by inflammatory status to test whether vagus nerve stimulation works best in those with elevated inflammation.
- •Depression framed as heterogeneous rather than a single mechanism
- •Evidence discussed: cytokine administration can induce depression; SSRIs may have anti-inflammatory effects in some contexts
- •Interoception described as the brain sensing inflammatory status through organ-to-brain vagus signaling
- •Research proposal: stratify depression by inflammatory markers and test VNS response differences
- 1:43:27 – 1:57:10
Pain overreaction analogy, immune cell switching (M1→M2), and inflammation ‘engrams’ in the brain
The conversation moves from Tim’s chronic low back pain to the idea of inflammatory overreaction—why similar imaging findings can produce pain in some people but not others. Dr. Tracey explains how vagus-linked spleen signaling can shift immune cells from a more destructive to a more healing state. He then describes Asya Rolls’ work suggesting the brain can form memory-like neural networks (“engrams”) for inflammatory states and that reactivating those networks can re-induce inflammation, and he shares that his team is mapping distinct engrams for different cytokines.
- •Low back pain framed as potentially disproportionate ‘alarm’ responses to similar physical findings
- •Vagus-to-spleen pathway described as shifting macrophage/monocyte states from M1 to M2 as a healing-oriented change
- •Engram concept applied to inflammation: neural networks can ‘remember’ inflammatory states and potentially reinstate them when reactivated
- •Dr. Tracey reports ongoing work indicating distinct brain networks for TNF versus IL-1 exposure in mice
- 1:57:10 – 2:06:24
Why neck ‘vagus’ devices might still help: nonspecific stimulation and nervous system integration
Tim asks how cervical (neck) stimulation devices could work if they likely don’t directly reach the vagus nerve. Dr. Tracey explains anatomical barriers and reiterates that skin-applied devices aren’t direct vagus stimulation, while also acknowledging FDA-approved evidence of benefit for migraine in some devices. He offers a framework from Charles Sherrington: because nervous system reflexes interconnect, nonspecific inputs to the nervous system may still produce downstream effects through integrated routing in brain/spinal cord circuits, even if the precise mechanism is unknown.
- •Anatomical explanation of why surface stimulation is unlikely to directly reach the vagus within the carotid sheath
- •Acknowledgment that some neck devices have FDA-approved migraine indications and outperform controls statistically
- •Sherrington’s ‘integrative action’ idea used to explain how nonspecific stimulation can still influence outputs
- •Multiple plausible pathways suggested (muscle relaxation, vascular effects, central routing into other autonomic outputs), with mechanism uncertainty emphasized
- 2:06:24 – 2:13:47
Closing: Dalai Lama meeting, ‘blue energy’ meditation imagery, and careful optimism
To wrap up, Dr. Tracey shares a story about presenting vagus nerve science at a meeting hosted by the Dalai Lama in New York state. The Dalai Lama’s questions about vagus anatomy align with a meditation visualization described by monks as channels of energy down both sides of the neck into the abdomen. Dr. Tracey closes by endorsing lifestyle practices as beneficial while cautioning against presenting them as cures for serious inflammatory illnesses, emphasizing the promise of clinically tested vagus-based immunoregulation.
- •Dr. Tracey’s conference experience with the Dalai Lama and scientists, including a session summarizing the meeting on stage
- •Dalai Lama’s questions about whether the vagus is in front/back and whether there is one or two
- •Monks’ description of a meditation practice visualizing two streams of energy down the neck, chest, and into the abdomen
- •Final message: self-help practices can be helpful, but serious disease needs serious clinical pathways; the immunoregulator approach offers hope grounded in long science and clinical trials
